Speak directly to the analyst to clarify any post sales queries you may have.
The epilepsy therapeutic market in APAC is forecasted to grow by USD 449.35 mn during 2023-2028, accelerating at a CAGR of 4.19% during the forecast period. The report on the epilepsy therapeutic market in APAC provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet need for disease-modifying treatment, increase in patient population having epilepsy, and rising awareness regarding epilepsy.
The epilepsy therapeutic market in APAC is segmented as below:
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
By Product
- First-generation epilepsy therapeutics
- Second-generation epilepsy therapeutics
- Third-generation epilepsy therapeutics
This study identifies the reformation of marketed epilepsy drugs as one of the prime reasons driving the epilepsy therapeutic market in APAC growth during the next few years. Also, the emergence of new-generation AEDS and AEDS with novel mechanism action will lead to sizable demand in the market.
The report on the epilepsy therapeutic market in APAC covers the following areas:
- Epilepsy therapeutic market in APAC sizing
- Epilepsy therapeutic market in APAC forecast
- Epilepsy therapeutic market in APAC industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epilepsy therapeutic market in APAC vendors that include Alkem Laboratories Ltd., Bausch Health Companies Inc., BIAL, Dr Reddys Laboratories Ltd., Eisai Co. Ltd., H Lundbeck AS, Johnson and Johnson, Novartis AG, Pfizer Inc., Sanofi SA, SK Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and GlaxoSmithKline Plc. Also, the epilepsy therapeutic market in APAC analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary
The publisher recognizes the following companies as the key players in the epilepsy therapeutic market in APAC: Alkem Laboratories Ltd., Bausch Health Companies Inc., BIAL, Dr Reddys Laboratories Ltd., Eisai Co. Ltd., H Lundbeck AS, Johnson and Johnson, Novartis AG, Pfizer Inc., Sanofi SA, SK Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and GlaxoSmithKline Plc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is reformation of marketed epilepsy drugs.'
According to the report, one of the major drivers for this market is the high unmet need for disease-modifying treatment.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alkem Laboratories Ltd.
- Bausch Health Companies Inc.
- BIAL
- Dr Reddys Laboratories Ltd.
- Eisai Co. Ltd.
- H Lundbeck AS
- Johnson and Johnson
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- SK Inc.
- Sumitomo Pharma Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- UCB SA
- GlaxoSmithKline Plc
